These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33738859)

  • 1. Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity.
    Soukup J; Cesak T; Hornychova H; Manethova M; Michnova L; Netuka D; Vitovcova B; Cap J; Ryska A; Gabalec F
    Histopathology; 2021 Sep; 79(3):406-415. PubMed ID: 33738859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
    Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
    Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
    Asa SL; Mete O; Riddle ND; Perry A
    Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature.
    Chinezu L; Vasiljevic A; Trouillas J; Lapoirie M; Jouanneau E; Raverot G
    Eur J Endocrinol; 2017 Feb; 176(2):195-201. PubMed ID: 27913611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
    Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
    Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas.
    Mayr B; Buslei R; Theodoropoulou M; Stalla GK; Buchfelder M; Schöfl C
    Eur J Endocrinol; 2013 Oct; 169(4):391-400. PubMed ID: 23847328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone (GH) and prolactin (PRL) gene expression and immunoreactivity in GH- and PRL-producing human pituitary adenomas.
    Li J; Stefaneanu L; Kovacs K; Horvath E; Smyth HS
    Virchows Arch A Pathol Anat Histopathol; 1993; 422(3):193-201. PubMed ID: 8493775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly.
    Soukup J; Hornychova H; Manethova M; Michalova K; Michnova L; Popovska L; Skarkova V; Cesak T; Netuka D; Ryska A; Cap J; Hána V; Hána V; Kršek M; Dvořáková E; Krčma M; Lazurova I; Olšovská V; Starý K; Vaňuga P; Gabalec F
    J Cell Mol Med; 2021 Mar; 25(5):2484-2492. PubMed ID: 33491286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stem Cell Transcription Factor Sox2 Is Expressed in a Subset of Folliculo-stellate Cells of Growth Hormone-Producing Pituitary Neuroendocrine Tumours and Its Expression Shows No Association with Tumour Size or IGF1 Levels: a Clinicopathological Study of 109 Cases.
    Soukup J; Česák T; Hornychová H; Michalová K; Michnová Ľ; Netuka D; Čáp J; Gabalec F
    Endocr Pathol; 2020 Dec; 31(4):337-347. PubMed ID: 32632839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA Methylation Pattern in Somatotroph Pituitary Neuroendocrine Tumors.
    Kober P; Rymuza J; Baluszek S; Maksymowicz M; Nyc A; Mossakowska BJ; Zieliński G; Kunicki J; Bujko M
    Neuroendocrinology; 2024; 114(1):51-63. PubMed ID: 37699356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactin and Growth Hormone Signaling and Interlink Focused on the Mammosomatotroph Paradigm: A Comprehensive Review of the Literature.
    Araujo-Castro M; Marazuela M; Puig-Domingo M; Biagetti B
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular cells in pituitary neuroendocrine tumors.
    Delfin L; Mete O; Asa SL
    Hum Pathol; 2021 Aug; 114():1-8. PubMed ID: 33991528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medical Therapies in Functioning Pituitary Neuroendocrine Tumors(PitNETs)].
    Nagamine T; Fukuda I
    No Shinkei Geka; 2023 Jul; 51(4):706-715. PubMed ID: 37491068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor.
    Kola B; Korbonits M; Diaz-Cano S; Kaltsas G; Morris DG; Jordan S; Metherell L; Powell M; Czirják S; Arnaldi G; Bustin S; Boscaro M; Mantero F; Grossman AB
    Clin Endocrinol (Oxf); 2003 Sep; 59(3):328-38. PubMed ID: 12919156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plurihormonal Pituitary Neuroendocrine Tumours - A Single Centre Experience.
    Mihajlović M; Pekić S; Doknić M; Stojanović M; Rašić D; Miljić D; Petakov M; Manojlović Gačić E
    Int J Surg Pathol; 2024 May; 32(3):470-477. PubMed ID: 37438981
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical and Proteomic-Based Molecular Characterizations of Invasive and Noninvasive Somatotroph PitNETs.
    Chen M; Duan L; Sun W; Guo Z; Miao H; Yu N; Yang S; Wang L; Gong F; Yao Y; Zhu H
    Neuroendocrinology; 2023; 113(9):971-986. PubMed ID: 37253344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours.
    Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
    Endocr Pathol; 2021 Sep; 32(3):408-414. PubMed ID: 33694064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptomic Classification of Pituitary Neuroendocrine Tumors Causing Acromegaly.
    Rymuza J; Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Nyc A; Baluszek S; Zieliński G; Kunicki J; Bujko M
    Cells; 2022 Nov; 11(23):. PubMed ID: 36497102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokeratin CK 7 and CK 20 expression in pituitary adenomas.
    Coons SW; Estrada SI; Gamez R; White WL
    Endocr Pathol; 2005; 16(3):201-10. PubMed ID: 16299403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas.
    Lee JC; Pekmezci M; Lavezo JL; Vogel H; Katznelson L; Fraenkel M; Harsh G; Dulai M; Perry A; Tihan T
    Endocr Pathol; 2017 Dec; 28(4):287-292. PubMed ID: 28994039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.